**Table 1:**

***All published studies that reported the effectiveness or safety of Hydroxychloroquine, Chloroquine, or Azithromycin***

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Country** | **Case definition** | **No.**  **Patients**  **(Intervention / standard care)** | **Age**  **( Intervention-standard care)** | **Sex**  **(Total male percentage)** | **Treatment** | **Duration (days)** | **Primary Outcomes** | | **Findings** |
| **Type of study** | **Intervention** |
| **Control** |
| **Borba 2020 (24)** | Brazil | Clincally suspected adults with severe COVID, | 81  (41:40) | 47.4 ± 13.3 | 75.3 % males | HCQ 600 bid | 23 Mar – 5 Apr 2020 | Lethality until day 13 | | 39%(high dose) and 15% (low dose) |
| RCT | HCQ 450 bid day 1, 450 OD further 4 days |
| **Chang 2020(25)** | USA | COVID-19 positive | 117  (HCQ:66  HCQ+AZ:51) | Total:60.2 ± 14.9 | 59.5% males | HCQ 400mg bid for 1 d then 200mg bid for 4 d | ------- | assess QTc | | 32.1±25.1ms (HCQ)  35.7±28.9ms (HCQ+AZ)., p=0.66 |
| Prospective cohort | HCQ as before +AZ |
| **Chen.J 2020(26)** | China | PCR-confirmed COVID-19 | 30  (15:15) | HCQ: 50.5 ± 3.8.  SC: 46.7 ± 3.6 | HCQ: 60% males  SC:80% males | HCQ 400 mg/d for 5 d | 6 Feb – 25 Feb 2020 | PCR conversion One week after hospitalization | | 86.7% (HCQ) and 93.3%(SC) |
| RCT | SC |
| **Chen. Z 2020(27)** | China | Covid-19 | 62  (1:1) | Mean age (SD) ( Intervention 44.1 (16.1)  Standard care 45.2 (14.7) | |  | | --- | | ( Intervention 45.2% males  Standard care 48.3% males | | HCQ 400 od | 4 Feb – 28 Feb 2020 | Absorption of pneumonia in CT  Clinical improvement | | 80.6% (HCQ) and 54.8% (SC)  Shorter duration of cough and fever in HCQ group.  Two patients experienced side effect (HCQ).  Four paients deterirated in the (SC) |
| RCT | SC |
| **Chong, 2020(28)** | China | Covid-19 | 11 | 51.55± 12.54 | 63.6% males | Lopinavir/  ritonavir  400/100 mg; bid for 14 days+  HCQ 400 mg bid day‐1 then 200 mg bid for 2‐5) | N/A | Developed QT prolongation | | 27.3% developed prolonged QTc |
| Case-series |
| **Gautret, 2020(29)** | France | PCR positive mildly infected Covid-19 patients | 80 | Median (IQR)  52.5 (42-62) | 53.8% males | HCQ 200 mg tid for 10 d  + AZM 500 mg for 1 d then 250 mg/d for 4 d | 3-21 March 2020 | Clinical course, viral clearance and hospital stay | | Clinical course:81.3% with favorable outcome  Viral clearance: 93% had viral clearance at Day8  Hospital stay: mean length of stay of 4.6 days |
| Retrospective observational |
| **Gautret, 2020(29)** | France | PCR confirmed COVID-19 patients | 36  (HCQ:14  HCQ+AZ:6  SC:16) | Total HCQ 51.2 ± 18.7  SC: 37.3 ± 24.0 | Total HCQ: 45% males  SC: 37.5% males | HCQ 200 tid for 10 d | Early march-16 march | Virological cure | | 57.1% (HCQ) , 100% (HCQ+AZ) and 12.5% (SC) |
| Clinical trial | HCQ as before +AZ: loading 500mg then 250mg /d for 4 d |
| SC |
| **Geleris, 2020(30)** | USA | All Hospitalized adult patients with positive COVID-19 infection | 1376  (811:565) | ----------- | HCQ: 58.4% male  SC:54.3% male | HCQ 600 mg bid one day then 400 mg/d for 4 days | 7 Mar – 8 Apr 2020 | Composite of time to intubation or death (time-to-event analysis) | | No significant association between HCQ and intubation or death (hazard ratio, 1.04; 95% CI: 0.82–1.32) |
| Observational | SC |
| **Gerard, 2020(31)** | France | Reports of cardiotoxicity associated with HCQ, CQ, AZM, or LOPI use in COVID-19. | 120 | 64.3 ± 13.4 | 76.7%; | HCQ/CQ/AZM/ LOPI | ---- | Cardiac adverse drug reactions | | HCQ 86%, AZM 60%. Lopinavir-ritonavir 14% and CQ 2.5%. |
| Survey |
| **Hraiech, 2020(32)** | France | COVID-19 PCR positive ICU patients | 45 (HCQ+AZM 17, Lopinavir/ ritonavir 13, SC 15) | HCQ+AZM:60 ± 17  Lopinavir/ ritonavir: 62 ± 13  SC:60 ± 16 | HCQ+AZM:88% males  Lopinavir/ ritonavir: 69% males  SC:73% males | HCQ 600 mg and AZM 500 then 250 mg/d | 2 Mar – 31 Mar 2020 | Viral clearance at day 6 treatment | PCR was negative in 5/13 (38%) from the lopinavir–ritonavir group, 3/17 (1%) from the HCQ–azithromycin group and 2/15 (20%) from the control group. | |
| Lopinavir–ritonavir 800 mg/d |
| Case control | SC |
| **Macías. 2020(33)** | Spain  Retrospective cohort | patients with autoimmune inflammatory diseases with confirmed or suspected COVID 19 | (290:432) | 56 (45-65) | M HCQ (17.1%) | HCQ vs no HCQ (for autoimmune disease) | 27 Feb – 16 April 2020 | Incidence of COVID 19 in patients receiving vs not receiving HCQ | | 5 cases (1.7%) in those on HCQ vs 5 cases (1.2%) in those not on HCQ |
| **Mahévas 2020(34)** | France | severe acute respiratory syndrome | 173  (84 / 89) | Median (IQR)  HCQ: 59 (48-67)  SC: 62 (54-69) | HCQ: 77% males  SC: 67% males | HCQ 600 mg/d | 12 Mar – 31 Mar 2020 | the survival rate at day 21 without transfer to ICU | | 76% (HCQ) and 75% (SC) |
| Comparative observational | SC |
| **Rosenberg, 2020(35)** | USA | Lab confirmed COVID-19 | 1438  (HCQ+AZ:735  HCQ :271  AZ:211  SC:221) | Median  (HCQ+AZ:61.4  HCQ :65.5  AZ:62.5  SC:64) | HCQ+AZ:62  HCQ :58.3  AZ:63.5  SC:49.8 | HCQ+AZ | 15 Mar – 28 Mar 2020 | Mortality | | 25.7% (HCQ+AZM), 19.9% (HCQ), 10% (AZM) and 12.7% (SC) |
| HCQ |
| AZ |
| SC |
| Retrospective cohort |  |
| **Stroppa, 2020(36)** | Italy | COVID-19, Cancer patients | 25 Cancer patients,31 Non-cancer patients | ) 71.64 ± 10.08 | 80% males in cancer patients, 48% males in Non-cancer patients | 7 days or HCQ 400mg OD alone or AV+HCQ | 21-February 21, 2020 to March 18, 2020 | Mortality | | Of the 25 cancer patients, nine (36%) are dead and 16 (64%) arealive, with improvement from pneumonia, in the control group of patients hospitalized and treated with the same  protocol in the same period, 16.13% are dead and 83.87% are alive p = 0.12. |
| Case control |
| **Broek, 2020 (37)** | Netherlands | Hospitalized and suspected with COVID-19 | 95 patients | Median  65 (min18-max 91) | 66.3% males | CQ 600mg then 300mg bid for 5 d | 8-27 March 2020 | Assess the degree of CQ induced QTc prolongation in hospitalized COVID-19 patients | | 22 patients (23%) had a QTc interval exceeding 500ms |
| Retrospective observational study |
| **Voisin, 2020(38)** | France | Hospitalized patients with COVID- 19 pneumonia | 50 patients | Median  68 (53-81) | 55.2% males | HCQ 600/d for 6 d + AZM 500mg/d for 1 d then 250mg/d for 2-5 d | 18 March - 25 March 2020 | Effect of HCQ+AZ combination on QTc in case of short term treatment of COVID 19 | | 38 patients (76 %) presented short term  modifications of QTc (> 30 ms). |
| Cohort | N/A |
| **Yu,2020 (39)** | China | Confirmed COVID-19 in critically ill adult patients | 550  (48 / 502) | Median (IQR)  HCQ: 68 (60-75)  SC: 68 (59-77) | HCQ: 66.7% males  SC: 62.2% males | HCQ 200 bid (7-10 days) | February 1, 2020 to April 4 , 2020 | Mortality & inflammatory cytokines level | | Mortality: 18.8% (HCQ) and 47.7% (SC)  IL-6 reduced from 22.2 (8.3–118.9) pg/ml to 5.2 (3.0–23.4) pg/ml (HCQ) but no change in (SC) |
| Retrospective cohort | SC |
| **Huang, 2020 (b) (40)** | China | Confirmed COVID-19 patients | 22  CQ:10  Lopinavir/Ritonavir:12 | CQ:41.5 (33.8–50.0) Lopinavir/Ritonavir: 53.0 (41.8–63.5) | CQ:30% Lopinavir/Ritonavir: 50% | CQ 500 bid for 10 d | January 27, 2020 to February15, 2020 | Virological cure, CT scan improvement and hospital discharge at day 14 | | Virological cure :100% (HCQ) and 91.7% (Lopinavir/Ritonavir)  CT scan improvement:100% (HCQ) and 75% (Lopinavir/Ritonavir)  Hospital discharge:100% (HCQ) and 50% (Lopinavir/Ritonavir) |
| Case control | Lopinavir/Ritonavir 400/100 mg bid for 10 d |
| **Magagnoli,2020(41)** | USA | Lab confirmed COVID-19  hospitalized patients | 807  ( HCQ: 198  HC+AZ:214  SC:395) | Median  HCQ: 71 (62–76.8) ,  HCQ+AZ :68 (59–74)  SC: 70 (59–77) | HCQ: 97%  HCQ+AZ :95.3%  SC: 95.2% | HCQ 400/d for 5 d | March 9,  2020 and April 29, 2020 | Mortality & mechanical ventilation | | Mortality: HCQ aHR, 1.83; 95% CI, 1.16–2.89; p = 0.009, but HCQ+AZM aHR, 1.31; 95% CI, 0.80–2.15; p = 0.28. compared to SC  Mechanical ventilation: HCQ aHR, 1.19; 95% CI, 0.78–1.82; p =0.42 but in the HC+AZ aHR, 1.09; 95% CI, 0.72–1.66; p = 0.69, compared to SC |
| Retrospective cohort | HCQ 422/d + AZM for 5 d |
| SC |
| **Ramireddy, 2020(42)** | USA | COVID-19 Confirmed/suspected patients | 98 (27 AZM - 10 HCQ - 61 AZ+ HCQ) | 62.3 ± 17 | 61% males | HCQ+AZM | 1 February 2020 to 4 April, 2020 | QT prolongation | | Significant prolongation in men (12% of patients) reached critical QTc prolongation.  Changes in QTc were highest with the combination group compared to either drug alone, with many-fold greater prolongation with the combination vs. azithromycin alone (17±39 vs. 0.5±40 ms, p=0.07) |
| Case-series | HCQ 400 bid on day1 then 200 bid on days 2 to 5 |
| AZM either 500mg daily or 500 mg on day1 followed by 250mg daily on days 2-5. |
| **Barbosa, 2020(43)** | USA | PCR positive COVID-19 patients | 63  (32/ 31) | HCQ: 61.8 ± 15  SC:63.7±15.4 | HCQ: 46.9% males  SC: 71% males | HCQ 400mg bid for 1-2 days then 200-400mg/d for 3-4days | 15 March 2020 -31 March 2020 | Mortality rate | | 12.9% (HCQ) and 3.13% (SC) |
| Retrospective cohort | SC |
| **Mallat,2020(44)** | UAE | Hospitalized adult patients with confirmed SARS-CoV-2 infection | 34  (23/ 11) | HCQ: 33 (31-48)  SC: 41 (30-55) | HCQ: 73.9% males  SC: 72.7% males | HCQ 400 mg bid for 1 day, then 400 mg/d for 10 days. | 1 March - 25 March, 2020 | The time to SARS-CoV-2 negativity | | 17(13-21) days HCQ and 10(4-13) days SC |
| Retrospective cohort | SC |
| **Huang, 2020(3)** | China | Confirmed COVID-19 cases | 373  (197/ 176 | CQ: 43.8 ±13.1  SC:45.6±13.5 | CQ:49% SC:45% | HCQ 500/d | 7 Feb-8 March 2020 | Median Time to undetectable viral RNA | | 3(3-5) HCQ and 9(6-12) SC. |
| Prospective Observational | SC |
| **Feng, 2020(45)** | China | Confirmed COVID-19 cases | 50  (25/25) | median  CQ: 51 (41 - 62)  SC: 46 (38 - 67) | Male: (50.4%) | CQ 500mg bid | Jan 17- Feb. 28 2020 | 1ry outcome: development of severe pneumonia | | None of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%; P =0.074) |
| Retrospective cohort | SC |
| **Mathian,2020(46)** | France | SLE with COVID-19 | 17 patients on HCQ | 53.5 (26.6–69.2) | 23.5% males | HCQ | 29 March- 6 April 2020 | Clinical curse | | Admitted to hospital (82%); needed O2 therapy (64.7), ICU admission (41%) Respiratory complications: ARDS (29%) RF (65%) Pneumonia (76%) Acute renal failure (17.6%), hemodialysis (11.8%) Discharge (36%), Death (14%), remained in hospital (50%) |
| Case series | N/A |
| **Tang 2020(47)** | China | patients hospitalized with PCR confirmed mild to moderate COVID–19 | 150  (75/ 75) | HCQ 48.0± 14.1.  SC 44.1 ± 15.0 | HCQ: Males= 42(56%), SC Males= 40 (53%) | HCQ 1200 for 3d then 800/d for 14-21 d | 11 to 29 February | Rate of viral negative conversion at 28 days | | (56/75 (74.6%) in SC and 53/75 (70.6%) in HCQ) negatively converted before 28 days |
| RCT | SC |
| **Carlucci, 2020(48)** | USA | PCR positive COVID-19 patients | 931  Zinc+HCQ+AZ:411  HCQ+AZ:521 | Zinc+HCQ+AZ: 63.19 ± 15.18  HCQ+AZ: 61.83 ± 15.97 | Zinc+HCQ+AZ:64.3% males  HCQ+AZ:61.4% males | HCQ 400 mg/d for 1 d then 200 mg bid for 5d +AZ 500 mg/d for 5 d+ zinc sulfate 220 mg bid for 5 d | 2 March 2020 to 5 April 2020 | Effect of adding zinc to HCQ and AZM | | The addition of zinc sulfate did not impact the length of hospitalization, duration of ventilation, or ICU duration. |
| retrospective observational | The same dose as in the other group but without zinc |
| **Singh, 2020(49)** | USA | Confirmed COVID-19 patients | 1820  (910 /910) | HCQ:62.17±16.81  SC:62.55±17.62) | HCQ: 53.96% males  SC: 54.94% males | HCQ  (dose not mentioned) | 20 January, 2020, to 1 May , 2020 | Mortality 30-Day & Need for mechanical ventilation | | Mortality: 11.34% (HCQ) and 11.98% (SC)  Mechanical ventilation: 5.05% (HCQ) and 6.26% (SC) |
| SC |
| Retrospective cohort |
| **Regina, 2020(50)** | Switzerland | laboratory confirmed SARS-CoV-2 patients | 200 | 70.0 years [IQR 55.0-81.0] | Male, 60% |  | from March 1 to March 25, 2020 | Need for mechanical ventilation (MV)at day 14 | | HCQ: (31.2%)  Remdisivir: (100%)  Protease inbititors: (31%)  Tocilizumab:(82%) |
| Retrospective cohort |  |
| **Membrillo,2020(51)** | Spain | laboratory confirmed SARS-CoV-2 patients | 166  ( 123 / 43)  83 patients had mild clinical picture at admission, 48 moderate and 35 severe. | HCQ: 61.5 (16.2)  SC: 68.7 (18.8) | HCQ: 61.8% males  Non HCQ: 62.8% males | Loading dose of HCQ 800 mg + 400 mg, followed by maintenance dose of 400 mg /d | -NA | Mortality | | 48,8 % of patients not treated with HCQ died versus 22% in the group of HCQ (p=0,002).  HCQ increased the mean cumulative survival in the mild moderate & severe group to 1,8 ,1.4, 1,6 times respectively but difference was statistically significant in the mild group. |
| Observational Cohort | SC |
| **Lee, 2020(52)** | South Korea | Confirmed COVID-19 patients | 72  (LPV/r:45  HCQ:27 | Median (IQR)  LPV/r: 39 (24–56)  HCQ: 37 (24–53) | LPV/r: 44.4%  HCQ:44.4% | LPV/r: 400/100 mg/d bid | February 21, 2020 to March 21,2020 | Compare clinical  outcomes of both treatments | | Disease progression (HCQ) 44% and (LPV/r) 18% |
| Retrospective cohort | HCQ:400mg/d |
| **Million, 2020(53)** | France | PCR positive COVID-19 patients | 1061 | 43.6 ± 15.6 | 46.4% male | HCQ 200 mg tid for 10 d + AZM 500 mg on day 1 followed by 250 mg/d for 4 d | March 3rd to March 31st | Death, clinical worsening and viral shedding persistence (> 10 days). | | 91.7% had good clinical outcome and virological cure, 4.4% had viral shedding persistence and 0.75% died |
| Retrospective cohort |
| **Okour, 2020(54)** | USA | Confirmed COVID-19 patients | 36 Patient | Not provided | Not provided | HCQ +/- AZM | March 2020 | probability of negative-PCR in patients. | | odds of positive-PCR decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds decrease by 61%, and by 12% for each day increase, and for azithromycin co-treatment, respectively. |
| Non RCT |
| **Saleh, 2020(55)** | USA | Confirmed COVID-19 patients | 201  CQ:10  HCQ: 191  from the previous sample 119 received AZ | 58.5±9.1 | Males (57.2%) | CQ 500 mg  bid for 1 d then 500 mg/d for 4 d or  HCQ 400mg bid for 1 d then 200 mg bid for 4 d | March 1-23,2020 | Assess QT prolongation resulting in Torsade de pointes | | 440.6±24.9 ms (HCQ/CQ) and 439.9±24.7 ms (HCQ/CQ + AZM) (P=0.834) |
| Prospective cohort | The same doses as before + AZM 500 mg/d for 5 days |
| **Chorin,2020 (56)** | USA | COVID-19 patients | 251 patients | 64±13 | 75% males | HCQ 400 mg bid for 1 d then  200 mg bid for 4 days.  + AZM was  500 mg/d for 5 d | --------- | Assess the change in QTc | | QTc >500 ms, occurred in 23% of patients. |
| Retrospective cohort |

AZ: azithromycin; HCQ: hydroxychloroquine; CQ: cholooroquine; SC: standard care; PCR: Polymerase chain reaction; ICU: intensive care unit; CT: computed tompgraphy; IQR: interquartile range; RCT: randomized control trial; LPV/r :Lopinavir/ritonavir